Updated

A clinical trial found that retatrutide, an experimental obesity drug that simultaneously targets the GLP-1, GIP, and glucagon hormone pathways, helped participants lose up to 25% of their body weight, making it the most potent weight-loss drug tested to date. The results position retatrutide as a potential successor to existing GLP-1 drugs like Ozempic and Wegovy, intensifying competition in the booming obesity-drug market and raising hopes for even greater efficacy in future treatments.